Introduction Patients with uterine carcinosarcoma (UCS) have a dismal prognosis despite receiving extensive treatment which also may abate the quality of life (QoL). Our aim is to determine the survival in patients with UCS and to assess the QoL during and after treatment.
Methods An observational study was performed in the Erasmus Medical center between 2016 – 2021, including all patients with UCS. Clinical data was collected from diagnosis until 5 years after treatment or death. EORTC QLQ-C30 and -EN24 were obtained at four time points: pre-operative, end of treatment (ET), one year, and two year after treatment. QLQ-C30 outcomes were also compared with normative data of a matching reference group.
Results 52 patients were included in the study, with a mean age of 69 years (range 50–86 years) at the time of diagnosis. The majority of patients were diagnosed with early-stage disease (N=20, N=5, N=9, N=18 patients respectively with FIGO stage I-IV). Median overall survival (OS) was 18 months, with the poorest survival seen in patients with stage IV disease (median OS=9 months) (figure 1). QoL assessment indicated that patients with advanced stage disease reported significantly more deterioration on insomnia, financial problems, tingling/numbness and hair loss. Furthermore, comparing QLQ-C30 outcomes at ET showed a significant difference compared to normative data in overall quality of life, role, emotional, cognitive and social functioning (figure 2).
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.